Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.83 USD | 0.00% | +5.78% | +44.09% |
May. 21 | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
May. 16 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 13.16M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.98
x | P/E ratio 2025 * |
-1.39
x | Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.32% |
Latest transcript on Inhibikase Therapeutics, Inc.
1 week | +5.78% | ||
Current month | +24.49% | ||
1 month | -2.14% | ||
3 months | -17.57% | ||
6 months | +110.34% | ||
Current year | +44.09% |
Managers | Title | Age | Since |
---|---|---|---|
Milton Werner
FOU | Founder | 61 | 08-08-31 |
C. Warren Olanow
CTO | Chief Tech/Sci/R&D Officer | - | 21-01-03 |
Surendra Singh
COO | Chief Operating Officer | - | 14-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dennis Berman
BRD | Director/Board Member | 73 | 19-08-31 |
Paul Grint
BRD | Director/Board Member | 66 | 20-12-21 |
Milton Werner
FOU | Founder | 61 | 08-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 1.83 | 0.00% | 15 086 |
24-05-23 | 1.83 | -3.17% | 28,337 |
24-05-22 | 1.89 | 0.00% | 29,703 |
24-05-21 | 1.89 | +1.61% | 36,882 |
24-05-20 | 1.86 | +7.51% | 121,107 |
Delayed Quote Nasdaq, May 24, 2024 at 01:28 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.09% | 13.16M | |
+68.96% | 62.86B | |
-0.88% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.56% | 26.46B | |
-22.15% | 18.9B | |
+4.67% | 12.67B | |
+24.54% | 12.27B | |
+28.21% | 12.07B |
- Stock Market
- Equities
- IKT Stock